Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Harvard Bioscience makes and sells the specialized lab instruments and equipment that scientists use to study living things.
Harvard Bioscience is a small company that sells the tools scientists use to study living things. If a drug company or a university lab wants to test a new medicine on living tissue, or grow cells in a dish, or measure how a tiny organ responds to a chemical, Harvard Bioscience makes much of the hardware that makes that work possible. Its products include pumps that move fluids precisely, instruments that test tissue and organs outside the body, and equipment for growing and studying cells in the lab. The customers are mostly researchers — pharmaceutical companies, universities, and government labs — who buy these tools because they need results they can trust and repeat.
The name can be confusing. Harvard Bioscience has no connection to Harvard University. It started in 1901 as a small maker of lab gear near Boston and later grew by buying up other instrument companies. Today it is headquartered in Holliston, Massachusetts, and it is a genuinely tiny business — total annual revenue has run in the low hundreds of millions of dollars, and it sells thousands of different products, each in small quantities. That is the key to understanding the economics: no single product is a blockbuster. Instead, the company carries a wide catalog and relies on customers buying many different items from one trusted supplier. The business has had a rough patch. Late in 2024, Harvard Bioscience disclosed accounting problems tied to how it had been recognizing revenue and how it tracked inventory, which forced it to restate financial results and delayed its reports. The company brought in new leadership and worked to fix the controls. That matters to investors because trust in the numbers is the whole ballgame for a small company. The underlying products sell to a steady base of scientific customers, but the company is small enough that a stumble in its books or a slowdown in research spending can hit it hard.
In 1901, Dr. William T. Porter had a problem: students learning physiology needed good equipment to actually practice on, and there wasn't much around. So he started building high-quality teaching gear himself, down in the basement of Harvard Medical School. It worked out pretty well — Porter went on to help found the American Journal of Physiology and became a big name in the field.
For years the company had been using the Harvard Bioscience name informally, but it only made things official in 2000. The Harvard names come with strings attached: they're used under a license with Harvard University, a friendly arrangement, not an ownership claim.
That same year, the company sold shares to the public for the first time, and the timing was good — the IPO left it with roughly $40 million in cash to work with.
In 2013, the company separated its regenerative medicine device business, which made tools for growing and repairing tissue, into its own public company. That let the core business focus on plain research tools while the spun-off unit chased its own ambitious goals.
By 2018 the company was reshaping its portfolio: it bought Data Sciences International, a Minnesota-based firm, for about $71 million, and at the same time sold off its Denville Scientific unit for around $20 million.
Chane Graziano stepped down as CEO in 2019, and James Green took over as President and CEO. Under Green, the company's performance weakened in the back half of his six years in charge.
The numbers told the story: revenue slipped to about $116 million in 2019 from nearly $121 million the year before, and the company carried $55 million in loans. Management announced a restructuring — closing the Connecticut operation, downsizing in the United Kingdom, and cutting more than a tenth of its workforce.
By 2025 the situation was rough: the stock had fallen about 88% over the past year. John Duke took over as President and CEO that July, succeeding Jim Green, and the board was rebuilt with new independent directors.
Things started to steady. In December 2025 the company refinanced its debt, lining up a $40 million credit facility with BroadOak Capital, which gave it a stronger balance sheet after a long stretch of financial strain.
Now the company is pitching a bigger idea: moving from a plain seller of lab tools to a bridge between lab research and real human treatments — what it calls Translational Science. The plan rests on four pillars: organoid and 3D biology, a pipeline of new products, growing consumables revenue, and running the business better. Early signs are encouraging, with preliminary fourth-quarter 2025 revenue of about $24 million and adjusted EBITDA up 27% from a year earlier.
Its competition comes from bigger instrument makers and from many niche rivals, and its main vulnerability is that lab equipment budgets are among the first things to get trimmed when research funding tightens. What makes it durable, when things go right, is the long tail of customers who keep coming back for consumables and replacement parts. It is not a fast-growing tech story. It is closer to a steady supplier of the unglamorous metal and plastic that science quietly runs on.
Saved answer · last researched 6 Nov 2026